Rani Therapeutics announces preliminary pharmacodynamic data on GLP-1

Rani Therapeutics announced pharmacodynamic data of an incretin triagonist of the GLP-1, GIP, and glucagon receptors delivered transenterically, which mimics the RaniPill route of administration. This follows Rani‘s prior study demonstrating oral delivery of a GLP-1 receptor agonist with high bioavailability via the RaniPill capsule. Data Highlights: The recent preclinical study evaluated the pharmacokinetic and pharmacodynamic profiles of an incretin triagonist when delivered via an endoscope-guided transenteric administration to mimic the RaniPill route of administration, versus the traditional administration route of subcutaneous injection. The study was conducted in canines separated into two groups. In Group 1, 0.12 mg/kg of drug was administered via transenteric delivery by endoscope. In Group 2, 0.12 mg/kg of drug was administered by subcutaneous injection. Blood samples were collected over 2 weeks for analysis of serum drug concentrations and various PD and safety biomarkers. The drug was well tolerated in both groups with no serious adverse events observed or changes in safety markers examined. Near-Term Milestone Expectations: Initiation of Phase 2 clinical trial of RT-102, a RaniPill GO containing teriparatide for osteoporosis, expected in 2024. Topline results of Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, expected in the first quarter of 2024. Development of RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024.